Literature DB >> 6164783

In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide.

K H Dangman, B F Hoffman.   

Abstract

We studied the effects of N-acetyl procainamide (NAPA) on isolated canine cardiac tissues by using standard microelectrode techniques. NAPA (10-40 mg/l) does not suppress the rate of phase 4 depolarization of Purkinje fibers and does not change resting membrane potential, action potential amplitude or maximum upstroke velocity of phase O of the action potentials of Purkinje fibers or ventricular muscle cells. In contrast, action potential duration of both types of cells is significantly prolonged by NAPA in a dose-dependent manner. In toxic concentrations (80-240 mg/l), NAPA can produce a "secondary plateau" at about -55 mV during phase 3 of the action potential of Purkinje fibers driven at cycle lengths of 2000 to 4000 msec. Early afterdepolarizations and single or multiple spontaneous action potentials were often triggered during the secondary plateau. When NAPA is given to conscious or anesthetized dogs (50-100 mg/kg i.v.), ventricular extrasystoles occur at constant coupling intervals if the basic rate of ventricular activation is slow (60 per minute or slower). Single extrasystoles, or the first extrasystole in a salvo, appear at coupling intervals of 400 to 600 msec. The single and multiple extrasystoles induced by NAPA may be caused by action potentials triggered during the secondary plateau and may degenerate into ventricular fibrillation. In doses of up to 100 mg/kg i.v., NAPA exerts slight antiarrhythmic effects in dogs with 24-hr myocardial infarcts.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6164783

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

Review 1.  Impact of recent molecular studies on evaluation of ventricular arrhythmias.

Authors:  D M Roden
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

Review 2.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?

Authors:  F A Fish; D M Roden
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

Review 4.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Authors:  Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

Review 5.  Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

6.  Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K+ current blocker.

Authors:  G N Beatch; S Abraham; B A MacLeod; N R Yoshida; M J Walker
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

Review 7.  Genetics of acquired long QT syndrome.

Authors:  Dan M Roden; Prakash C Viswanathan
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 8.  Clinical use of and future perspectives on antiarrhythmic drugs.

Authors:  Juan Carlos Estrada; Dawood Darbar
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

9.  Class III antiarrhythmic drugs (amiodarone, bretylium and sotalol) on action potentials and membrane currents in rabbit sino-atrial node preparations.

Authors:  H Satoh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

10.  Effects of bepridil on transmembrane action potentials recorded from isolated canine cardiac tissues. Studies on normal and infarct-zone Purkinje fibres and ventricular muscle cells.

Authors:  K H Dangman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.